AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04939545 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: Intercostal continuous loco-regional placebo solution (NaCl 0,9%) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h. As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis.
Study NCT06481800 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cnotrol group
Description: Routine medical care for RLS and sleep quality in hemodialysis Anemia management, electrolyte balance,Avoiding caffeine and alcohol, establishing a regular sleep schedule leg care,Medicines that increase dopamine in the brain, affecting calcium channels, Opioids , Gabapentin and Pregabali , Benzodiazepines,Regular monitoring of kidney function, blood tests
Study NCT06481800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD)
Description: Manual lymphatic drainage (MLD) for 20 minutes within after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients
Study NCT05783583 — intervention group
Intervention type: DEVICE
Intervention: Remote Digital Slit Lamp
Description: Slit Lamp Examination
Study NCT04975633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bodyport Cardiac Scale
Description: Patients will be instructed to take daily measurements for 90 days. Data will be transmitted to Bodyport and concerning findings (weight gain, change of impedance, elevated heart rate) will be reported back to the medical team. The medical team will either choose to act on the information given or continue to observe trends. Interventions may include titration of therapy, change in therapy, fluid restriction, sodium restriction and lifestyle modification
Study NCT06503731 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC - prefilled syringe
Description: Subcutaneous efgartigimod PH20 SC given by prefilled syringe
Study NCT06503731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo PH20 SC - prefilled syringe
Description: Subcutaneous placebo PH20 SC given by prefilled syringe
Study NCT06503731 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PH20 SC - prefilled syringe
Description: Subcutaneous placebo PH20 SC given by prefilled syringe
Study NCT06136559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Administered orally
Study NCT06136559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Administered orally
Study NCT06136559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acalabrutinib
Description: Administered orally
Study NCT06537232 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greens-based Supplement
Description: Participant will consume one serving of greens-based supplement per day in the morning, for 30 days.
Study NCT05061368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: Phosphodiesterase Type 5 inhibitor. Known to potentiate nitric oxide mediated vasodilation.
Study NCT05061368 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05694286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Juvederm Volbella XC hyaluronic acid dermal filler injection
Description: Infraorbital filler injection
Study NCT06422390 — intervention group
Intervention type: BIOLOGICAL
Intervention: Platelet - Rich Plasma
Description: Platelet - Rich Plasma is a biologic injection created from the patient's own blood. 52cc of the patient's blood is drawn then mixed with 8cc of anticoagulant. The blood mixture will be spun down using a centrifuge that can separate the platelet-rich plasma from the other contents in the blood. Once the centrifuge process is complete the Platelet - Rich Plasma is ready to be used.
Study NCT06396338 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders.
Study NCT05818137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: SC injection at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 21 days plus background PAH therapy.
Study NCT06363409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal Bar as a recovery food snack
Description: Cereal bar as a recovery snack food
Study NCT06363409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond
Description: Almond as a recovery snack food
Study NCT05713474 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic EMG exam with microEMG
Description: Diagnostic EMG exam with microEMG
Study NCT06348771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: monounsaturated fatty acids (MUFA) peanut meal
Description: mixed meal tolerance test and postprandial measurements
Study NCT06348771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: monounsaturated fatty acids (MUFA) peanut meal
Description: mixed meal tolerance test and postprandial measurements
Study NCT06285643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2-GDNF Gene therapy
Description: Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose
Study NCT06285643 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control Surgery
Description: Bilateral partial burr/twist holes without dural penetration
Study NCT06244316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF concentration 1
Description: Recombinant Human Nerve Growth Factor (rhNGF) concentration 1 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
Study NCT06244316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF concentration 2
Description: Recombinant Human Nerve Growth Factor (rhNGF) concentration 2 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
Study NCT06244316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo solution)
Description: Eye drop solution, containing no rhNGF. 1 drop in each eye three times a day for 4 weeks of treatment.
Study NCT05461339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB014 Monoclonal Antibody Injection
Description: intravitreal injection at 1.25mg once every 4 weeks
Study NCT05461339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection [Lucentis]
Description: intravitreal injection at 0.5mg once every 4 weeks
Study NCT05384431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Muscle5 and TRIM7
Description: Intake of MUSCLE 5 and TRIM 7 supplements on a daily basis for 12 weeks
Study NCT05384431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed exercise
Description: Mixed exercise (aerobic and resistance) three days per week for 12 weeks
Study NCT05384431 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mixed exercise
Description: Mixed exercise (aerobic and resistance) three days per week for 12 weeks
Study NCT04043598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
Study NCT04043598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
Study NCT04948333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001 40mg BID
Description: One tablet of 40 mg will be taken orally twice a day (BID)
Study NCT04948333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001 80mg QD
Description: Two tablets of 40 mg will be taken orally once a day (QD)
Study NCT04948333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001 200mg QD
Description: Five tablets of 40 mg will be taken orally once a day (QD)
Study NCT06499623 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Albumin, C-Reactive Protein, Cholesterol, Urea, Creatinine, Vitamin D
Study NCT06499623 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical Impedance Analysis
Description: Total Impedance, Segmental Muscle Analysis, Segmental Fat Analysis, Absolute Muscle Mass Value, Muscle Mass Index, Total Body Fat Percentage, Total Body Water, Phase Angle Measurement
Study NCT06499623 — intervention group
Intervention type: OTHER
Intervention: Nutritional Risk Assessment Questionnaire
Description: Fill in the Questionnaire of the Working Group on Nutritional Care in Oncology and get nutrition risk score. The objective data includes weight loss in 6 months, current BMI and food tolerance, and oncological diagnosis including ongoing anti-cancer treatment.
Study NCT06193577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phaseolus Vulgaris L. Dry Extract
Description: Extracts of Phaseolus vulgaris (beans) in association with a balanced diet are known to reduce glycaemia and food intake in rodents and humans thus promoting weight loss.
Study NCT06470022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Evolut FX
Description: TAVI performed with Medtronic Evolut FX
Study NCT06193577 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo control does not contain active ingredients.
Study NCT06470022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Edwards Sapien 3 Ultra Resilia
Description: TAVI performed with Edwards Sapien 3 Ultra Resilia
Study NCT05281744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia Care Consultation program
Description: The Dementia Care Consultation program uses a telephone-based intervention to provide an in-depth, personalized service for individuals living with ADRD and their care partners. It consists of comprehensive needs assessments, creation and implementation of personalized care plans, monitoring and revising care plans, disease education and support coaching, referrals to community-based organizations for service and support, and access to assistance.
Study NCT06142136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D substitution with sublingual sprayable microemulsion.
Description: Participants received sublingual sprayable microemulsion of vitamin D3 4000 IU daily for 30 days.
Study NCT06142136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D substitution with oil droplets
Description: Participants received oil droplets of vitamin D3 4000 IU daily for 30 days.
Study NCT06142136 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D substitution with capsules
Description: Participants received capsules of vitamin D3 4000 IU daily for 30 days.
Study NCT05671861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trismus Device Prototype
Description: Device is noninvasive and will be inserted between patient's upper and lower teeth
Study NCT05671861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Surveys will be administered to participants
Study NCT05671861 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: A study-specific, accompanying secure mobile application for users to track progress will be created.
Study NCT04681339 — intervention group
Intervention type: OTHER
Intervention: Antibiotic treatment
Description: Antibiotic treatment
Study NCT04681339 — intervention group
Intervention type: OTHER
Intervention: No antibiotic treatment
Description: No antibiotic treatment
Study NCT05238025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV vaccine
Description: One injection, suspension for injection, intramuscular use, 0.5mL MVA-BN-RSV virus with a titer of at least 3 x 10E8 infectious units (Inf.U)/0.5mL in a Tris buffer at pH 7.7.
Study NCT05478980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Night Time Tea
Description: Night-time Tea
Study NCT05478980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Tea
Description: Feel New Tea
Study NCT04654988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone: 1 mg/kg daily for 4 weeks followed by gradually tapered dose for 5 months
Study NCT04654988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Azathioprine: 2 mg/kg daily for 12 months
Study NCT04654988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Prednisone
Description: Placebo Prednisone
Study NCT04654988 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Azathioprine
Description: Placebo Azathioprine
Study NCT05889884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended maxillary fixed retainer
Description: Bonding extended maxillary fixed retainer from right first maxillary premolar to left maxillary first premolar for 6 months then assessment of relapse using 3D superimposition , little index , lateral cephalometric assessment along with PDL assessment with quality of life ,function and speech assessment
Study NCT05794048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatocellular carcinoma
Description: Tumor and liver biopsy
Study NCT05794048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pancreatic adenocarcinoma
Description: Tumor and pancreatic biopsy
Study NCT05794048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pancreatic neuroendocrine tumor
Description: Tumor and pancreatic biopsy
Study NCT04786379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Irrigation and Debridement
Description: Patients with confirmed septic arthritis treated with multiple small incisions to perform irrigation and debridement with partial synovectomy.
Study NCT04786379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Arthrotomy with irrigation and debridement
Description: Patients with confirmed septic arthritis treated with a single large incision, open arthrotomy to perform irrigation and debridement with partial synovectomy.
Study NCT05238025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tris Buffered Saline (TBS)
Description: One injection, solution for injection, intramuscular use, 0.5mL TBS, pH 7.7.
Study NCT06239467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKI-219
Description: Oral twice daily
Study NCT03843463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram 10mg
Description: Escitalopram tablet
Study NCT03843463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic escitalopram 10 mg tablet
Study NCT03843463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-delivered naming treatment
Description: 15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke
Study NCT03843463 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computer-delivered naming treatment
Description: 15 45-minute sessions of computer-delivered naming treatment beginning two months following stroke
Study NCT06365710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Telerehabilitation program
Study NCT06239467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Intramuscular injection
Study NCT06239467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Intravenous (IV)
Study NCT06365710 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: Guided rehabilitation program with physiotherapist appointments
Study NCT06186427 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-GPFAPI-04 PET/CT
Description: The same group of patients underwent 68Ga-DOTA-GPFAPI-04 PET/CT and FDG PET/CT examinations respectively
Study NCT05476835 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: respiratory exercises - incentive spirometer - walking
Description: respiratory exercises (in form of diaphragmatic breathing, pursed lip breathing exercise and incentive spirometer), rehab exercise program and walking exercise.
Study NCT05756777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Dose level (-1) 80mg, (1) 120mg, (2) 120mg
Study NCT05756777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Dose level (-1) 250mg, (1) 250mg, (2) 500mg
Study NCT05756777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enasidenib
Description: Dose level (-1) 50mg, (1) 50mg, (2) 100mg
Study NCT05629689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection / GEH200521 (18F) Injection - Part A
Description: Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
Study NCT05629689 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic and Static - PET/CT scan
Description: Dynamic whole-body PET/CT scan starting at the time of injection (sequential scans over 90 minutes anticipated) followed by static whole-body scans starting at 150 minutes, 270 minutes, and (optional) 24 hours after injection.
Study NCT05713474 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional EMG
Description: Diagnostic EMG exam with conventional EMG
Study NCT05293028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F527
Description: 0.001、0.01、0.1、0.3、1、3 and10 mg/kg QW
Study NCT05133128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples
Study NCT05629689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection / GEH200521 (18F) Injection - Part B
Description: Administration of GEH200520 Injection followed within 2 to 4 minutes by GEH200521 (18F) Injection followed by a 10mL saline flush
Study NCT05629689 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static - PET/CT scan
Description: Whole-body PET/CT scan (up to 30 min). Exact timing will be determined from Part A. An optional dynamic scan may be acquired in addition to the required whole-body PET/CT scan at each imaging visit.
Study NCT04931823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPO-100
Description: Docetaxel albumin-bound
Study NCT06093165 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Re-irradiation
Description: 20Gy on 10 fractions
Study NCT04990869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside
Description: The patients will receive 1 g of Nicotinamide Riboside or placebo orally every morning and evening for 6 weeks.
Study NCT04990869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06345729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1084
Description: Oral tablets
Study NCT06345729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Oral tablets
Study NCT06345729 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT06345729 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV infusion
Study NCT05977426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: In the study, women received four Reiki sessions once a week for four weeks from the researchers with Usuı Shiki Ryoho Reiki 1
Study NCT05647525 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Perform autoimmune encephalitis titer tests
Description: We only follow up without intervention.
Study NCT05265715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low AGE diet
Description: The recommended daily AGE intake will be either:~* 7,500 kilounits \[ku\], which is a 50% reduction from the average 15,000 ku consumed by most adults or~* a 50% reduction from their baseline AGE intake (based on 3-day food AGE record)
Study NCT05265715 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Research blood draw
Description: Baseline (Week 0), Week 4, Week 12, and Week 24 (end of intervention)